ZA201204476B - Beta-carbolines for use in the treatment of hearing loss and vertigo - Google Patents

Beta-carbolines for use in the treatment of hearing loss and vertigo

Info

Publication number
ZA201204476B
ZA201204476B ZA2012/04476A ZA201204476A ZA201204476B ZA 201204476 B ZA201204476 B ZA 201204476B ZA 2012/04476 A ZA2012/04476 A ZA 2012/04476A ZA 201204476 A ZA201204476 A ZA 201204476A ZA 201204476 B ZA201204476 B ZA 201204476B
Authority
ZA
South Africa
Prior art keywords
carbolines
vertigo
beta
treatment
hearing loss
Prior art date
Application number
ZA2012/04476A
Other languages
English (en)
Inventor
Hans Rommelspacher
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of ZA201204476B publication Critical patent/ZA201204476B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/04476A 2009-12-28 2012-06-18 Beta-carbolines for use in the treatment of hearing loss and vertigo ZA201204476B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
ZA201204476B true ZA201204476B (en) 2014-01-29

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/04476A ZA201204476B (en) 2009-12-28 2012-06-18 Beta-carbolines for use in the treatment of hearing loss and vertigo

Country Status (17)

Country Link
US (1) US9107914B2 (enExample)
EP (1) EP2519238B1 (enExample)
JP (1) JP5627705B2 (enExample)
KR (1) KR20120098855A (enExample)
CN (1) CN102844029A (enExample)
AU (1) AU2010338669A1 (enExample)
BR (1) BR112012015967B1 (enExample)
CA (1) CA2785233C (enExample)
DE (1) DE112010005017A5 (enExample)
IL (1) IL220661A (enExample)
IN (1) IN2012DN05066A (enExample)
MX (1) MX2012007678A (enExample)
NZ (1) NZ600478A (enExample)
RU (1) RU2012132429A (enExample)
SG (1) SG181599A1 (enExample)
WO (1) WO2011079841A1 (enExample)
ZA (1) ZA201204476B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
SI2968284T1 (sl) 2013-03-14 2021-08-31 Osteoqc Inc. Alkil-amin harmin derivati za pospeševanje rasti kosti
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP7695496B2 (ja) 2018-08-14 2025-06-19 オシフィ セラピューティクス リミティド ライアビリティ カンパニー フルオロβ-カルボリン化合物
EP3836923B1 (en) 2018-08-14 2024-10-16 OssiFi Therapeutics LLC Pyrrolo - dipyridine compounds for the treatment of bone loss
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3849530A4 (en) 2018-09-12 2022-06-22 Hough Ear Institute METHODS OF TREATMENT OF HEARING LOSS AFTER COCHLEAR IMPLANT SURGERY
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
EP1086101B1 (en) * 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
KR20120098855A (ko) 2012-09-05
JP5627705B2 (ja) 2014-11-19
IL220661A (en) 2016-03-31
WO2011079841A1 (de) 2011-07-07
IN2012DN05066A (enExample) 2015-10-09
IL220661A0 (en) 2012-08-30
RU2012132429A (ru) 2014-02-10
JP2013515752A (ja) 2013-05-09
EP2519238A1 (de) 2012-11-07
DE112010005017A5 (de) 2012-10-04
BR112012015967A2 (pt) 2016-04-19
CN102844029A (zh) 2012-12-26
SG181599A1 (en) 2012-07-30
BR112012015967B1 (pt) 2019-08-27
US9107914B2 (en) 2015-08-18
MX2012007678A (es) 2012-09-12
NZ600478A (en) 2013-10-25
CA2785233C (en) 2018-10-09
US20130028958A1 (en) 2013-01-31
AU2010338669A1 (en) 2012-06-21
CA2785233A1 (en) 2011-06-07
EP2519238B1 (de) 2014-08-13

Similar Documents

Publication Publication Date Title
IL220661A0 (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
GB2485291B (en) Cannabidiol for use in the treatment of generalised and/or partial seizures
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
EP2281188A4 (en) PHOTOACOUSTIC IMAGING DEVICES AND METHODS OF MAKING AND USING THE SAME
IL216955A0 (en) Medical devices and methods
IL209754A0 (en) Diazacarbazoles and methods of use
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
EP2231019A4 (en) PHOTOACOUSTIC IMAGING DEVICES AND IMAGING METHODS
EP2437743A4 (en) OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE
IL217357A0 (en) Vascular and bodily duct treatment devices and methods
IL216013A0 (en) Devices and methods for dermatological treatment
GB0815078D0 (en) Hyperbaric dressing and method
GB2470358B (en) Hyperbaric dressing and method
IL206125A0 (en) Azaindolizines and methods of use
PL2200600T3 (pl) Nerameksan do zastosowania w leczeniu podostrego szumu usznego
IL209548A0 (en) Diazacarbazoles and methods of use
GB0920258D0 (en) New medical agents and use thereof
EP2460615A4 (en) Laser treatment device and container-producing device
EP2427129A4 (en) DEVICES AND METHODS FOR MODIFYING FABRICS
IL211641A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
GB0905970D0 (en) Depsipeptides and their therapeutic use
EP2421552B8 (en) Collagen v for use in the treatment of asthma
IL219444A (en) Procine for use in the treatment of blood cell infections
GB2472681B (en) Gas treatment cell and apparatus incorporating same